Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic lock for suspected permi-cath infection in hemodialysis patients
IRCT20210214050352N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of vancomycin, ceftazidime and heparin in catheter infection (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Fever, Length of hospital stay and 1 more. Started Mar 2021; status: completed.
02
Drugs
vancomycinceftazidimeheparin
03
Conditions
catheter infection
Beyond the preview
Go deeper on IRCT20210214050352N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210214050352N1.